Raymond Osarogiagbon
Experienced in Breast Cancer

Dr. Raymond Osarogiagbon

Hematology Oncology | Hematology | Oncology
Laboratory Corporation Of America Holdings
7900 Airways Blvd Bldg B, 
Southaven,, MS 
Offers Telehealth
Experienced in Breast Cancer
Laboratory Corporation Of America Holdings
7900 Airways Blvd Bldg B, 
Southaven,, MS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Raymond Osarogiagbon is a Hematologist Oncology specialist and a Hematologist in Southaven,, Mississippi. Dr. Osarogiagbon is rated as an Experienced provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Nodules, Lung Adenocarcinoma, and Endoscopy.

His clinical research consists of co-authoring 163 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of Breast Cancer.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MS
Hospital Affiliations
Baptist Memorial Hospital Union County
Baptist Memorial Hospital Tipton
Baptist Memorial Hospital Desoto
Baptist Memorial Hospital-Crittenden, Inc
Baptist Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
HMO Partners
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Magnolia Health
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Laboratory Corporation of America Holdings
7900 Airways Blvd Bldg B, Southaven,, MS 38671
Call: 662-349-2442

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: Sotorasib
Study Phase: Phase 2
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Afatinib Dimaleate, Cetuximab
Study Phase: Phase 2/Phase 3
SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice
SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer
NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: September 26, 2023
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide, Paclitaxel, Pemetrexed
Study Phase: Phase 2
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as a Prophylaxis for Patients Receiving Chemotherapy With Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as a Prophylaxis for Patients Receiving Chemotherapy With Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
Enrollment Status: Completed
Publish Date: October 20, 2022
Intervention Type: Other
Study Phase: Not Applicable
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 17 Less Clinical Trials

163 Total Publications

Diagnostic Follow-up of Positive Results on Low-Dose Computed Tomography Screening in the Medicare Population.
Diagnostic Follow-up of Positive Results on Low-Dose Computed Tomography Screening in the Medicare Population.
Journal: Annals of internal medicine
Published: December 15, 2025
View All 163 Publications
Similar Doctors
Elite in Breast Cancer
Dr. Gregory Vidal
Hematology | Oncology
Elite in Breast Cancer
Dr. Gregory Vidal
Hematology | Oncology

The West Clinic, PLLC

6005 Park Ave, Suite 700, 
Memphis, TN 
 (2.2 miles away)
901-527-3391
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gregory Vidal is a Hematologist and an Oncologist in Memphis, Tennessee. Dr. Vidal is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Paget Disease of the Breast, and Colorectal Cancer.

Distinguished in Breast Cancer
Dr. Kurt Tauer
Hematology | Oncology
Distinguished in Breast Cancer
Dr. Kurt Tauer
Hematology | Oncology

The West Clinic, PLLC

1588 Union Ave, 
Memphis, TN 
 (8.5 miles away)
901-300-1562
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kurt Tauer is a Hematologist and an Oncologist in Memphis, Tennessee. Dr. Tauer is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Lung Cancer, and Familial Colorectal Cancer.

Philip Lammers
Distinguished in Breast Cancer
Dr. Philip Lammers
Hematology Oncology | Hematology | Oncology
Distinguished in Breast Cancer
Dr. Philip Lammers
Hematology Oncology | Hematology | Oncology

Baptist Cancer Center (Physicians)

2996 Kate Bond Rd Ste 100, 
Bartlett, TN 
 (6.8 miles away)
901-383-5570
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Philip Lammers is a Hematologist Oncology specialist and a Hematologist in Bartlett, Tennessee. Dr. Lammers is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Breast Cancer, Lung Cancer, Paget Disease of the Breast, and Angiosarcoma.

VIEW MORE BREAST CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Osarogiagbon's expertise for a condition
ConditionClose
  • Elite
  • Lung Cancer
    Dr. Osarogiagbon is
    Elite
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Lung Nodules
    Dr. Osarogiagbon is
    Elite
    . Learn about Lung Nodules.
    See more Lung Nodules experts
  • Non-Small Cell Lung Cancer (NSCLC)
    Dr. Osarogiagbon is
    Elite
    . Learn about Non-Small Cell Lung Cancer (NSCLC).
    See more Non-Small Cell Lung Cancer (NSCLC) experts
  • Distinguished
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Osarogiagbon is
    Distinguished
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • EGFR Positive Lung Cancer
    Dr. Osarogiagbon is
    Distinguished
    . Learn about EGFR Positive Lung Cancer.
    See more EGFR Positive Lung Cancer experts
  • Large-Cell Lung Carcinoma
    Dr. Osarogiagbon is
    Distinguished
    . Learn about Large-Cell Lung Carcinoma.
    See more Large-Cell Lung Carcinoma experts
  • Lung Adenocarcinoma
    Dr. Osarogiagbon is
    Distinguished
    . Learn about Lung Adenocarcinoma.
    See more Lung Adenocarcinoma experts
  • Pleuropulmonary Blastoma
    Dr. Osarogiagbon is
    Distinguished
    . Learn about Pleuropulmonary Blastoma.
    See more Pleuropulmonary Blastoma experts
  • Small Cell Lung Cancer (SCLC)
    Dr. Osarogiagbon is
    Distinguished
    . Learn about Small Cell Lung Cancer (SCLC).
    See more Small Cell Lung Cancer (SCLC) experts
View All 7 Distinguished Conditions
  • Advanced
  • Mesothelioma
    Dr. Osarogiagbon is
    Advanced
    . Learn about Mesothelioma.
    See more Mesothelioma experts
  • Experienced
  • Agranulocytosis
    Dr. Osarogiagbon is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Anal Cancer
    Dr. Osarogiagbon is
    Experienced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Angiosarcoma
    Dr. Osarogiagbon is
    Experienced
    . Learn about Angiosarcoma.
    See more Angiosarcoma experts
  • B-Cell Lymphoma
    Dr. Osarogiagbon is
    Experienced
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
  • Breast Cancer
    Dr. Osarogiagbon is
    Experienced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Carcinoid Syndrome
    Dr. Osarogiagbon is
    Experienced
    . Learn about Carcinoid Syndrome.
    See more Carcinoid Syndrome experts
View All 39 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.